RxDoctor Payments Data

Luke Lansman, MD

Family Medicine · Fremont, NENPI 1477110948

Payments from drug & device makers

$1,391in general payments, 2019–2025

Across 88 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$293
  • Lilly USA, LLC$194
  • Pfizer$128
  • AstraZeneca$110
  • Amgen$109
  • Boehringer Ingelheim$103
  • plus $453 from 20 others

What the payments were for

  • Food & beverage$1,391100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,391 in reported general payments places this provider in the 65th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$128,251
Medicare patients
184
Services billed
2,527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban126$74,065
JardianceEmpagliflozin68$50,565
MounjaroTirzepatide28$30,634
JanuviaSitagliptin Phosphate32$20,574
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$18,514
OzempicSemaglutide17$16,833
XareltoRivaroxaban13$15,599
FarxigaDapagliflozin Propanediol22$14,890
TrulicityDulaglutide13$10,202
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$5,890
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,715
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$5,548
SymbicortBudesonide/Formoterol Fumarate19$5,178
Atorvastatin Calcium401$3,746
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$2,933

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$128$74,065126 claims
Boehringer IngelheimJardiance$103$50,56568 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$194$41,78152 claims
MerckJanuvia$13$20,57432 claims
AstraZenecaFarxiga, Symbicort$110$20,06841 claims
Novo NordiskOzempic$293$16,83317 claims
Johnson & JohnsonXarelto$15$15,59913 claims
Sanofi-aventis U.S. LLCLantus$41$2,51813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Fremont

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →